Change over period: —
NSE · ALPA
ALPA LAB
-40.5% from the 52-week high · +11.0% above the low
Alpa Laboratories Ltd. is a pharmaceutical holding company, which engages in the manufactures of drugs and chemicals. The company is headquartered in Indore, Madhya Pradesh. The company went IPO on 2007-08-01. The firm is engaged in manufacturing pharmaceutical finished dosage forms. Its product range includes a variety of generic and over the counter (OTC) drugs in various finished dosage forms for both human and veterinary use. For human use it offers capsules such as Ampicillin Capsule IP/BP, Amoxycillin Trihydrate Capsule IP/BP, Cloxacillin Capsules IP/BP and Piroxicam Capsules IP BP; creams, gels and ointments, which include Lidocaine Hydrochloride Jelly IP/USP, Nitrofurazone Cream USP, Miconazole Cream IP/BP and Clobetasole Ointment/Cream BP; ear and eye drops, such as Benzylpenicillin Inj. IP/BP and Benzathine Penicillin Inj. IP/BP, and tablets, such as Albendazole Tablet IP/USP, Paracetamol Tablet IP/BP and Tinidazole Tablets IP/BP. Its veterinary products include boluses, such as Alpamin Bolus and Alpazole Bolus, and injections, such as Atropine Inj. B.Vet.C and others.
The short version. ALPA LAB reported revenue of ₹31 crore for Sep 2026, up 19.2% from a year earlier. Return on equity was 8.1% in Mar 2026. Promoter holding was 57.19% in Sep 2026, down 0.10 points over 8 quarters.
1 · The price
How has the stock traded?
ALPA LAB trades 40.5% below its 52-week high and 11.0% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹31 cr.
6.4 pts lower than a year earlier.
Revenue compounded at 5.9% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 31 | 24 | 31 | 29 | 26 | 19 | 40 | 26 |
| Net profit | -2 | 1 | 1 | 2 | 0 | 12 | -2 | 9 |
| Net margin % | -6.0 | 4.1 | 4.4 | 6.6 | 0.4 | 61.6 | -5.3 | 34.0 |
| EPS (₹) | -0.88 | 0.47 | 0.66 | 0.9 | 0.05 | 5.59 | -1.01 | 4.23 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Revenue | 106 | 112 | 109 | 92 | 112 | 98 | 86 |
| Net profit | 15 | 20 | 17 | 13 | 14 | 7 | 2 |
| Net margin % | 14.2 | 17.3 | 15.4 | 13.7 | 12.6 | 7.4 | 2.2 |
| EPS (₹) | 7.13 | 9.27 | 7.97 | 6.0 | 6.7 | 3.44 | 0.88 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 8.1% in Mar 2026; debt to equity is 0.01.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 8.1 | 11.4 | 11.0 | 9.4 |
| Return on capital % | 8.9 | 14.7 | 13.6 | 11.8 |
| EBITDA margin % | 15.7 | 20.7 | 18.6 | 17.1 |
| Net margin % | 12.3 | 14.4 | 13.6 | 12.3 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 5.9% | 3.6% |
| Profit CAGR | 5.9% | 15.7% |
4 · The owners
Who holds it, and are they adding?
Down 0.1 pts over 8 quarters.
Unchanged over 8 quarters.
Up 0.07 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 57.29 | 57.29 | 57.29 | 57.29 | 57.29 | 57.19 | 57.19 | 57.19 | -0.1 |
| FII | 0.35 | 0.4 | 0.36 | 0.35 | 0.36 | 0.38 | 0.35 | 0.35 | 0.0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0.07 | 0.07 | +0.07 |
| Public | 42.35 | 42.31 | 42.34 | 42.35 | 42.35 | 42.43 | 42.39 | 42.39 | +0.04 |
Mutual fund holdings · Oct 2026
0 schemes hold this stock
0 the month before.
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for ALPA LAB are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about ALPA LAB
What is the ALPA LAB share price?
ALPA LAB (ALPA) last closed at ₹50.64, down 1.84% on the day. Its 52-week range is ₹46.46 to ₹86.69.
What is the market cap of ALPA LAB?
ALPA LAB has a market capitalisation of about ₹109 crore. Its price-to-earnings ratio is 25.3.
How are ALPA LAB's latest results?
ALPA LAB reported revenue of ₹31 crore for Sep 2026, up 19.2% from a year earlier. Return on equity was 8.1% in Mar 2026. Promoter holding was 57.19% in Sep 2026, down 0.10 points over 8 quarters.
Who owns ALPA LAB?
As of Sep 2026, shareholding was: Promoter 57.19%, FII 0.35%, DII 0.07%, Public 42.39%.
How many mutual funds hold ALPA LAB?
0 mutual fund schemes held ALPA LAB in October 2026. That compares with 0 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.